Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Feher

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Biochimica Et Biophysica Acta|May 26, 2004
Two novel missense mutations in ABCA1 result in altered trafficking and cause severe autosomal recessive HDL deficiencyChristiane Albrecht, Kevin Baynes, Alessandro Sardini, et al.
Disease Markers|August 1, 2012
Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT studyBharti Mackness, Judit Marsillach, Robert S Elkeles, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 17, 2008
The effect of WNT5B IVS3C>G on the susceptibility to type 2 diabetes in UK Caucasian subjectsKlelia D Salpea, David R Gable, Jackie A Cooper, et al.
Diabetes, Obesity & Metabolism|June 16, 2026
Combining Sodium-Glucose Co-Transporter-2 Inhibitor Plus Glucagon-Like Peptide-1 Receptor Agonist for Glucose-Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real-World Clinical Practice (CombiKid Study)William Hinton, Mark Joy, Anna K Forbes, et al.
Eclinicalmedicine|February 2, 2024
Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional studyAnna K Forbes, William Hinton, Michael D Feher, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 23, 2024
A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care populationAnna K Forbes, William Hinton, Michael D Feher, et al.
Molecular Genetics and Metabolism|September 11, 2012
Novel mutations of ABCA1 transporter in patients with Tangier disease and familial HDL deficiencyTommaso Fasano, Paolo Zanoni, Claudio Rabacchi, et al.
The Lancet. Diabetes & Endocrinology|March 3, 2018
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD studyBoris Waldman, Jean-Claude Ansquer, David R Sullivan, et al.
Hypertension (Dallas, Tex. : 1979)|December 16, 2020
Association Between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients With Hypertension: An Observational Cohort StudyJames P Sheppard, Brian D Nicholson, Joseph Lee, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Biochimica Et Biophysica Acta|May 26, 2004
Two novel missense mutations in ABCA1 result in altered trafficking and cause severe autosomal recessive HDL deficiencyChristiane Albrecht, Kevin Baynes, Alessandro Sardini, et al.
Disease Markers|August 1, 2012
Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT studyBharti Mackness, Judit Marsillach, Robert S Elkeles, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 17, 2008
The effect of WNT5B IVS3C>G on the susceptibility to type 2 diabetes in UK Caucasian subjectsKlelia D Salpea, David R Gable, Jackie A Cooper, et al.
Diabetes, Obesity & Metabolism|June 16, 2026
Combining Sodium-Glucose Co-Transporter-2 Inhibitor Plus Glucagon-Like Peptide-1 Receptor Agonist for Glucose-Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real-World Clinical Practice (CombiKid Study)William Hinton, Mark Joy, Anna K Forbes, et al.
Eclinicalmedicine|February 2, 2024
Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional studyAnna K Forbes, William Hinton, Michael D Feher, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 23, 2024
A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care populationAnna K Forbes, William Hinton, Michael D Feher, et al.
Molecular Genetics and Metabolism|September 11, 2012
Novel mutations of ABCA1 transporter in patients with Tangier disease and familial HDL deficiencyTommaso Fasano, Paolo Zanoni, Claudio Rabacchi, et al.
The Lancet. Diabetes & Endocrinology|March 3, 2018
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD studyBoris Waldman, Jean-Claude Ansquer, David R Sullivan, et al.
Hypertension (Dallas, Tex. : 1979)|December 16, 2020
Association Between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients With Hypertension: An Observational Cohort StudyJames P Sheppard, Brian D Nicholson, Joseph Lee, et al.
Pageof 3